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Summary: The administration of large doses of selenium (Se) to rats leads to reduced serum levels of somatotropin
(growth hormone) and insulin-like growth factor-1 (IGF-1), followed by growth retardation. Similar experiments in
humans have been contradictory. The effects of wheat Se and selenomethionine supplementation were investigated
in healthy, Norwegian women. In study 1, the participants (n = 18) were given Se-rich bread with 100, 200 and
300 μ§ Se daily for 6 weeks. Initial serum Se concentration were 1.5 ± 0.2 μιηοΐ/ΐ (mean ± SD). Serum Se
increased in a dose-dependent manner in the three groups (p < 0.001). There was no effect on somatotropin and
IGF-1 at any of the Se doses given. In study 2 (n = 24), the effects of 400 μg selenomethionine daily for 15 weeks
were studied in a placebo controlled study. In the treatment group, serum Se concentrations increased by more than
100%. There was, however, no effect on serum somatotropin and IGF*1 concentrations, nor was there any effect
on IGF-binding proteins 1 and 3. Our results indicate that at normal or slightly increased intakes, Se has no effect
on the serum concentrations of these two hormones in healthy individuals.
Introduction mark and Norway to warn against Se supplements in
1989Growth retardation is a typical finding in animals ex-
posed to toxic doses of selenium (Se) (1,2, 3). It is also Due to import of Se-rich wheat from USA and Canada,
a regular finding in stocks with alkali disease, a Se tox- wheat is the main dietary source of Se in Norway. At
icity syndrome (for review, 1. c. (4, 5)). Growth retarda- least 50% of the Se in wheat is in the form of seleno-
tion seems to appear irrespective of Se being adminis- methionine (11), which is also used in a number of com-
tered in an inorganic or organic form (6, 7). Recently, mercial Se supplements. Numerous studies have demon-
Thorlacius-Ussing and coworkers reported that somato- strated that selenomethionine, as well as wheat Se, has
tropin treatment of selenite exposed rats restored their high bioavailability (12-16). The purpose of the two
normal growth rate although serum insulin like growth studies presented here was to study the effects of
factor 1 (IGF-1) concentrations were still subnormal (8, increasing daily amounts of wheat Se and selenomethio-
9). Moreover, when selenite exposure was discontinued, nine on the serum concentrations of somatotropin, IGF-
serum somatotropin concentrations returned to normal i, IGF-binding protein 1 and IGF-binding protein 3 in
while IGF-1 concentrations remained low. healthy, young, Norwegian women.
In a Danish Se supplementation trial 256 μg yeast Se
was given daily to rheumatics for six months, leading to
a significant reduction in the serum concentration of Methods
IGF-1 (10). The results of the animal studies and the
 We report here the results from two studies Study , was conducted
study in humans prompted the health authorities in Den- in 1989 with graded doses of wheat selenium, and the serum levels
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of Se have been published previously (15). Unpublished results
from that study indicated that wheat Se had no effects on serum
growth hormone and 1GF-1 concentrations. However, IGF-1 circu-
Fates bound to specific binding proteins, and it was important to
see wether Se treatment affected serum levels of these binding pro-
teins. Moreover, one could not exclude the possibility that some-
what higher Se doses might have an effect. A new study was, there-
fore, carried out in 1992 (study 2), with selenomethionine given at
the highest level that is, generally, deemed safe, and serum levels
of IGF binding proteins were measured.
Subjects
Study 1: Eighteen female students at the age of 20-26 volun-
teered to participate in the study, and written consent was given
by each subject, in complicance with the ethical standards then
in use.
Study 2: Twenty-four female students at the age of 20-40 parti-
cipated. All participants gave informed consent and the study pro-
tocol was approved by the Regional Ethics Committee of Medical
Research, Region II, Norway.
None of the participants in the two studies had taken Se-containing
supplements the last three months prior to the studies. They were
all in good health, and they were non-smokers. None of the sub-
jects were pregnant or lactating, and they used no medication. Four
participants in study 1 and seven in study 2 used oral contracep-
tives. In study 1; all subjects were encouraged to maintain their
usual daily routines and dietary habits during the study. In study 2,
16 out of the 24 participants were encouraged to eat as much fish
as possible, at least three dinner servings per week, during the
study. As the fish eating had no influence on any of the results
reported here, 'eaters and non-eaters' of fish were pooled in the
subsequent analyses. The initial values of serum Se, body mass
index and age are given in table 1.
dietary Se intake of 80 μg/10 MJ (17). With an average energy
intake of 9.2 MJ/day, the daily Se intake was estimated to be ap-
proximately 75 μg. Accordingly, the total Se intake in the interven-
tion period in study 1, corrected for the substituted normal bread
slices, was estimated to be 160 μ& 260 μg and 360 μg Se daily
for the three groups, respectively. In study 2 the total average Se
intake would be approximately 475 μg/d in the study group and 75
μg/d in the control group.
Analytical methods
The concentrations of Se in serum and blood were determined
by atomic absorption spectrometry using a hydride generator
system (Varian AA-1475, VGA-76) after digestion in a mixture
of nitric and perchloric acid (18, 19). The results are expressed
in μπιοΐ/ΐ.
Somatotropin was measured using an immunoradiometric assay de-
veloped at the Hormone laboratory. The intra- and inter-assay
precisions are 6% and 10%, respectively. The normal range for
women is 0.6-7.2 mIU/1.
IGF-1 was measured after extraction (CM 8) using a radioimmuno-
assay from Nichols Institute Diagnostics (USA). The intra- and
inter-assay precisions are 7% and 12%, respectively. The normal
range for women is 15-35 nmol/1.
IGF binding protein-1 was measured using an immunofluororfietric
assay developed at the Hormone laboratory. The intra- and inter-
assay precisions are 8% and 16%, respectively. The normal range
for women is 0.02-0.47 nmol/1.
IGF binding protein-3 was measured using a radioimmunoassay
from Diagnostic System Laboratories (USA). The intra- and inter-
assay precisions are 5% and 8%, respectively. The reference range
for women is 63-280 nmol/1.
Experimental design
Study I: The subjects were randomized into three groups. For six
weeks the participants were given Se-rich bread, group 1 (n = 6)
receiving 100 μg, group 2 (n = 6) 200 μ» and group 3 (n = 6) 300
μg Se per day. The slices replaced bread otherwise consumed dur-
ing the day.
Study 2: The subjects were randomized into 2 groups. Group 1
(n = 16) received 400 μg Se in the form of selenomethionine con-
taining tablets daily, while group 2 (n = 8) received placebo tablets
for 15 weeks.
Samples
Blood samples were obtained by venipuncture in the morning after
a 12-hour fast, in study 1 at weeks 0, 3 and 6, and in study 2 at
weeks 0 and 15.
Diet and supplements
Study 1: Whole grain wheat containing 10 mg/kg Se was obtained
from Mr. R. Marts, Bonesteel, South Dakota with the kind assis-
tance of Prof. Ο. Ε. Olson of South Dakota State University. The
wheat was ground, mixed with appropriate amounts of ordinary
Norwegian flour, and baked into bread giving 100, 200 and 300
μg Se per 100 g of bread, respectively.
Study 2: Selenomethionine and placebo tablets were kindly pro-
vided by Pharma Nord A/S, Denmark. The tablets were identical
in taste and appearance. Each active tablet contained 100 μg
selenomethionine, and both groups were given 4 tablets per day.
Previous analysis of Se intake in similar groups of Norwegian
women, using the duplicate portion technique, indicated a mean
Statistics
The large variances observed for some of the quantities measured
in this study are normal and may be an indicator for the use of
non-parametric statistics. In the present study, non-parametric
methods were in a few cases more powerful than the parametric,
but in no case did they give significant results. For conceptual
simplicity and ease of comparisons, we have therefore reported the
parametric results. Thus the changes in the clinical findings within
groups were tested for significance by paired t-test. Means between
the three groups were subjected to one-way analysis of variance
and compared by Duncan's multiple range test. A p-value less than
0.05 was considered statistically significant. The results are ex-
pressed as mean ± SD.
Tab. 1 Initial values (mean ± SD) of serum Se, body mass index
(BMI) and age.
n Serum
Se
(μτηοΐ/ΐ)
BMI
(kg/m2
height)
Age
(years)
Study 1:
Group 1: (100 μg/d Se) 6 1.4 ± 0.1 21 ± 1 24 ± 2
Group 2: (200 μg/d Se) 6 1.5 ± 0.2 20 ± 3 23 ± 3
Group 3: (300 μg/d Se) 6 1.6 ± 0.2 21 ± 1 23 ± 2
Study 2:
Group 1: (400 μg/d Se) 16 1.3 ± 0.1 21 ± 2 22 ± 1
Group 2: (placebo) 8 1.3 ±0.2 22 ± 3 25 ± 7
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Results
Serum and blood Se concentrations
The initial serum concentrations of Se were similar in
the different study groups in both studies (tab. 1). Serum
Se increased, as previously reported, in a dose-related
manner in study 1, i. e. by 0.25, 0.47 and 0.67 μπιοΐ/l in
the three groups, respectively (p < 0.001 (15). In the
selenomethionine-group (study 2), Se concentrations
increased by 1.99 and 3.29 μιηοΐ/ΐ (ρ < 0.001) in serum
and blood, respectively. Serum and blood concentrations
of Se were strongly correlated throughout the study.
There was no change in serum or blood Se concentra-
tions in the placebo group.
Somatotropin
Study 1: As shown in table 2, initial somatotropin con-
centrations varied between the groups, groups 1 and 2
being significantly different, ρ < 0.05, from group 3.
Mean concentrations for all groups increased by week
three (NS) and increased further in groups 1 and 2 by
week six (NS), while in group 3 a decline was found
after 6 weeks, resulting in almost identical growth hor-
mone concentrations by the end of the supplementation
period.
Study 2: There was a non-significant decline in somato-
tropin concentrations in the placebo group, but the two
groups had comparable concentrations during the whole
study (tab. 2).
Insulin-l ike growth factor-1 and binding
proteins
At group level, the elevated serum concentrations of Se
were not accompanied by altered IGF-1 concentrations
in any of the studies (tab. 2). Neither were there any
changes in IGF binding protein-1 and IGF binding pro-
tein-3 in the Se-supplemented groups in study 2, while
Tab. 2 Serum levels of somatotropin, IGF-1, IGF binding protein-1 and IGF binding protein-3.
Start Midway Final
Somatotropin (μΐυ/1)
Study 1:
Group 1 (100 μg/d Se)
Group 2 (200 μg/d Se)
Group 3 (300 μg/d Se)
Study 2:
Group 1 (400 μ§Λ1 Se)
Group 2 (placebo)
6.0
7.8
13.4
15.0
25.2
± 5.5a 12.6 ± 8.1
± 4.1 11.7± 6.2
± 4.9b 19.7 ± 8.9
±13.1
± 19.1
16.0
17.2
16.9
12.0
17.0
± 11.3
± 12.1
± 9.7
± 9.8
± 14.4
IGF-1 (nmol/1)
Study 1:
Group
Group
Group
Study 2:
Group
Group
1
2
3
1
2
(100 μg/d
(200 μg/d
(300 μg/d
(400 μg/d
(placebo)
Se)
Se)
Se)
Se)
25.5
31.8
28.3
28.4
24.8
± 2.3
± 7.2
± 6.2
± 5.4
± 7.4
25.5 ±
31.6±
27.2 ±
4.0
11
5
.9
.8
28.7
30.9
29.6
27.0
26.7
± 6.4
± 9.4
± 5.8
± 4.8
± 8.3
IGF binding protein-1 (nmol/1)
Study 2:
Group 1 (400 ,μ§Λ1 Se)
Group 2 (placebo)
0.100 ±
0.166 ±
0.12
0.18
0.104 ± 0.10
0.097 ± 0.06
IGF binding protein-3 (nmol/1)
Study 2:
Group 1 (400 μ&ά Se)
Group 2 (placebo)
164.3 ±39.9
208.8 ±+60.2
166.9 ± 33.6
161.7 ±36.7
Study 1: Somatotropin and IGF-1 initially, and after 3 and 6 weeks.
Study 2: Somatotropin, IGF-1, IGF binding protein-1 and IGF
bonding protein-3 initially and after 15 weeks of supplementation.
Results with different superscription letters denote values signifi-
cantly different at a given time (p < 0.05; Ditncanfs multiple-
range test).
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the concentration of both IGF-binding proteins de-
creased (NS) in the placebo group (tab. 2).
Correlat ions
There were no correlations between the serum levels of
Se and somatotropin in any of the study groups during
the two studies. The concentrations of serum Se corre-
lated weakly and positively (NS) with IGF-1 at the start
of the study in study 1, while the correlation was nega-
tive (NS) in study 2 (r = -0.40, p = 0.054). Blood Se
and serum IGF-1 concentrations showed a significant,
negative correlation at the start of study 2: r = -0.54,
p = 0.007, the corresponding correlation between serum
Se and IGF-1 being r = -0.40, p = 0.054. There was,
however, no correlation between these quantities at the
end of the study (fig. 1). Moreover, there was no correla-
tion between changes in the concentrations of serum Se
and IGF-1 in the two studies.
Neither initial IGF binding protein-1 and IGF binding
protein-3 concentrations nor changes in these analyses
correlated with 'serum Se concentrations at any point
during study 2.
Discussion
Animal studies have shown that strongly increased
blood Se values are associated with decreased serum
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Fig. 1 IGF-1 versus serum Se concentrations at the end of study
1 and study 2. In study l, r = 0.03 (NS), in study 2, r = -0.002
(NS).
levels of IGF-1, suggesting that Se may suppress the
secretion of growth hormone and/or IGF-1 (8-10). Our
data show, however, that normal or moderately
increased serum and blood concentrations of Se (1.3—
4.0 μπιοΐ/ΐ), corresponding to a supplementation with
wheat Se or selenomethionine in the 100-400 μg range,
have no effects on growth hormonQ ,and IGF-1 concen-
trations in healthy individuals. Our data do not rule out
the possibility that higher Se intake may lower growth
hormone and IGF-1 concentrations. Such serum concen-
trations would, however, approach sub-toxic levels, and
have little relevance regarding the safety of normal Se
supplementation (50—400 μg/d). Though our study
groups were fairly small, we would have detected a 15%
average decrease in IGF-1 concentrations as significant,
a much smaller decrease than observed by the Danish
group mentioned earlier. The modest IGF-1 lowering we
observed in study 2 would require 290 supplemented
subjects to attain signficance, and the clinical relevance
of this may well be questioned.
The negative correlation between IGF-1 and blood Se
seen at the start of study 2 should not be interpreted as
a causal relationship between the two quantities, since
this correlation disappeared upon Se supplementation.
The lack of correlation between serum (and blood)
levels of Se and IGF-1 in both studies corresponds well
with the findings of Salbe et al. (20), who found no
relation between serum Se and IGF-1 concentrations in
an epidemiological study in USA.
A Se-induced lowering of IGF-binding proteins, would
increase the clearance rate of IGF-1 (21), and thus be a
possible mechanism by which Se might lower IGF-1.
We found, however, no indication of a suppression of
either IGF binding protein-1 or IGF binding protein-3.
On the contrary, we observed a weak positive correlation
between changes in IGF binding protein-3 and serum-
Se, all subjects taken together. Thus, whatever influence
the IGF-binding proteins may have on IGF-1 serum
levels and bioavailability (21), moderate variations in
serum Se do not seem to have any impact in healthy in-
dividuals.
The metabolism of Se seems to be perturbed in rheuma-
toid arthritis (22). In this patient group, Se incorporation
into the Se-dependent enzyme glutathione peroxidase1)
is suppressed, and the polymorphonuclear leukocytes,
that ordinarily are among the Se-richest cells iri the
body, do not increase their Se content in response to Se
supplementation (22). In a rat model, high-dose selenite
supplementation resulted in a high accumulation of Se
in the anterior pituitary, especially in the secretory gran-
Glutathione peroxidase (EC 1.11.1.9)
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ules of the somatotrophs (23). The Se accumulation re-
sulted in impaired pituitary and hepatic function. It may
be speculated that a redistribution of Se may explain the
IGF-1 lowering effect of Se supplementation observed
in rheumatoid arthritis (10). Models for normal seleno-
methionine kinetics are developed in 1. c. (24). It may
also be speculated that the circulating proteolytic activ-
ity observed during several illness conditions (21), and
responsible for IGF binding protein-3 degradation, is
somehow effected by Se.
In summary, our results show that moderate Se supple-
mentation has no significant effects on serum levels of
growth hormone, IGF-1, IGF binding protein-1 and IGF
binding protein-3. Our results are thus in accordance
with the lack of epidemiological evidence for growth
retardation in moderately high-selenium areas of the
world.
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